Creation and characterization of a doxycycline-inducible mouse model of thyroid-targeted RET/PTC1 oncogene and luciferase reporter gene coexpression

Thyroid

Volumn 17, Issue 12, 2007, Pages 1181-1188

  Knostman, Katherine A B ^a   Venkateswaran, Anjli ^b   Zimmerman, Bevin ^a   Capen, Charles C ^a   Jhiang, Sissy M ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b CELL SIGNALING TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; MITOGEN ACTIVATED PROTEIN KINASE; SODIUM IODIDE SYMPORTER; TETRACYCLINE; THYROGLOBULIN;

AGE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; GENE EXPRESSION; LUCIFERASE REPORTER GENE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PTC1 ONCOGENE; REPORTER GENE; RET ONCOGENE; THYROID DISEASE; THYROID GLAND; TRANSGENE; TRANSGENIC MOUSE;

ANIMALS; ANTI-BACTERIAL AGENTS; CARCINOMA, PAPILLARY; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; DOXYCYCLINE; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; LUCIFERASES; MAP KINASE KINASE KINASES; MICE; MICE, TRANSGENIC; MODELS, GENETIC; PROTO-ONCOGENE PROTEINS C-RET; RECEPTORS, CELL SURFACE; SYMPORTERS; THYROID GLAND; THYROID NEOPLASMS;

EID: 37849047786     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2007.0224     Document Type: Article

References (32)

1. American Cancer Society 2007 Thyroid Cancer. American Cancer Society, Atlanta. Available at http://www.cancer.org.
2. Nikiforov YE 2002 RET/PTC rearrangement in thyroid tumors. Endocr Pathol 13:3-16.
3. Knauf JA, Kuroda H, Basu S, Fagin JA 2003 RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. Oncogene 22:4406-4412.
4. Knauf JA, Ouyang B, Croyle M, Kimura E, Fagin JA 2003 Acute expression of RET/PTC induces isozyme-specific activation and subsequent downregulation of PKCepsilon in PCCL3 thyroid cells. Oncogene 22:6830-6838.
5. Kim DW, Hwang JH, Suh JM, Kim H, Song JH, Hwang ES, Hwang IY, Park KC, Chung HK, Kim JM, Park J, Hemmings BA, Shong M 2003 RET/PTC (rearranged in transformation/ papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1. Mol Endocrinol 17:1382-1394.
6. Rabes HM, Demidchik EP, Sidorow JD, Lengfelder E, Beimfohr C, Hoelzel D, Klugbauer S 2000 Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-Chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clin Cancer Res 6:1093-1103.
7. Klugbauer S, Lengfelder E, Demidchik EP, Rabes HM 1995 High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident. Oncogene 11:2459-2467.
8. Fenton CL, Lukes Y, Nicholson D, Dinauer CA, Francis GL, Tuttle RM 2000 The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults. J Clin Endocrinol Metab 85:1170-1175.
9. Bongarzone I, Fugazzola L, Vigneri P, Mariani L, Mondellini P, Pacini F, Basolo F, Pinchera A, Pilotti S, Pierotti MA 1996 Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma. J Clin Endocrinol Metab 81:2006-2009.
10. Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA 1997 Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 57:1690-1694.
11. Jhiang SM, Caruso DR, Gilmore E, Ishizaka Y, Tahira T, Nagao M, Chiu IM, Mazzaferri EL 1992 Detection of the PTC/retTPC oncogene in human thyroid carcinomas. Oncogene 7:1331-1337.
12. Miki H, Kitaichi M, Masuda E, Komaki K, Yamamoto Y, Monden Y 1999 ret/PTC expression may be associated with local invasion of thyroid papillary carcinoma. J Surg Oncol 71: 76-81.
13. Jhiang SM, Sagartz JE, Tong Q, Parker-Thornburg J, Capen CC, Cho J-Y, Xing S, Ledent C 1996 Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 137:375-378.
14. Jhiang SM, Cho JY, Furminger TL, Sagartz JE, Tong Q, Capen CC, Mazzaferri EL 1998 Thyroid carcinomas in RET/PTC transgenic mice. Recent Results Cancer Res 154:265-270.
15. Cho JY, Sagartz JE, Capen CC, Mazzaferri EL, Jhiang SM 1999 Early cellular abnormalities induced by Ret/PTC1 oncogene in thyroid-targeted transgenic mice. Oncogene 18:3659-3665.
16. Santoro M, Chiappetta G, Cerrato A, Salvatore D, Zhang L, Manzo G, Picone A, Portella G, Santelli G, Vecchio G, FuscoA 1996 Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. Oncogene 12:1821-1826.
17. Cho JY, Leveille R, Kao R, Rousset B, Parlow AF, Burak WE, Jr., Mazzaferri E, Jhiang SM 2000 Hormonal regulation of radioiodide uptake activity and Na+/I- symporter expression in mammary glands. J Clin Endocrinol Metab 85:2936-2943.
18. Knostman KAB, Cho JY, Ryu KY, Lin X, McCubrey JA, Hla T, Liu CH, Di Carlo E, Keri R, Zhang M, Hwang DY, Kisseberth WC, Capen CC, Jhiang SM 2004 Signaling through 3′,5′-cyclic adenosine monophosphate and phosphoinositide-3 kinase induces sodium/iodide symporter expression in breast cancer. J Clin Endocrinol Metab 89:5196-5203.
19. Hsieh CL, Xie Z, Liu ZY, Green JE, Martin WD, Datta MW, Yeung F, Pan D, Chung LW 2005 A luciferase transgenic mouse model: visualization of prostate development and its androgen responsiveness in live animals. J Mol Endocrinol 35:293-304.
20. Lemmen JG, Arends RJ, van der Saag PT, van der Burg B 2004 In vivo imaging of activated estrogen receptors in utero by estrogens and bisphenol A. Environ Health Perspect 112: 1544-1549.
21. Seethammagari MR, Xie X, Greenberg NM, Spencer DM 2006 EZC-prostate models offer high sensitivity and specificity for noninvasive imaging of prostate cancer progression and androgen receptor action. Cancer Res 66:6199-6209.
22. Xu ZL, Mizuguchi H, Ishii-Watabe A, Uchida E, Mayumi T, Hayakawa T 2001 Optimization of transcriptional regulatory elements for constructing plasmid vectors. Gene 72:149-156.
23. Buckwalter TLF, Venkateswaran A, Lavender M, La Perle KMD, Cho J-Y, Robinson ML, Jhiang SM 2002 The roles of phosphotyrosines-294, -404, and -452 in RET/PTC1-induced thyroid tumor formation. Oncogene 21:8166-8172.
24. Rhoden KJ, Unger K, Salvatore G, Yilmaz Y, Vovk V, Chiappetta G, Qumsiyeh MB, Rothstein JL, Fusco A, Santoro M, Zitzelsberger H, Tallini G 2006 RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma. J Clin Endocrinol Metab 91:2414-2423.
25. Nikiforov YE 2006 RET/PTC rearrangement - a link between Hashimoto's thyroiditis and thyroid cancer . . . or not. J Clin Endocrinol Metab 91:2040-2042.
26. Komminoth P, Roth J, Muletta-Feurer S, Saremaslani P, Seelentag WK, Heitz PU 1996 RET proto-oncogene point mutations in sporadic neuroendocrine tumors. J Clin Endocrinol Metab 81:2041-2046.
27. Lora MS, Waguespack SG, Moley JF, Walvoord EC 2005 Adrenal ganglioneuromas in children with multiple endocrine neoplasia type 2: a report of two cases. J Clin Endocrinol Metab 90:4383-4387.
28. Smith-Hicks CL, Sizer KC, Powers JF, Tischler AS, Costantini F 2000 C-cell hyperplasia, pheochromocytoma and sympathoadrenal malformation in a mouse model of multiple endocrine neoplasia type 2B. EMBO J 19:612-622.
29. Takahashi M, Ritz J, Cooper GM 1985 Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 42:581-588.
30. Kistner A, Gossen M, Zimmermann F, Jerecic J, Ullmer C, Lubbert H, Bujard H 1996 Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci USA 93:10933-10938.
31. Urlinger S, Baron U, Thellmann M, Hasan MT, Bujard H, Hillen W 2000 Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc Natl Acad Sci USA 97:7963-7968.
32. Agha-Mohammadi S, O'Malley M, Etemad A, Wang Z, Xiao X, Lotze MT 2004 Second-generation tetracycline-regulatable promoter: repositioned tet operator elements optimize transactivator synergy while shorter minimal promoter offers tight basal leakiness. J Gene Med 6:817-828.